An intravenous biological therapy for psoriasis: Infliximab
DOI:
https://doi.org/10.3126/jcmsn.v7i1.5977Keywords:
Infliximab, monoclonal antibody, dex, quality of life.Abstract
Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course and is associated with joint disease. The significant reduction in quality of life and the psychosocial disability suffered by patients underline the need for prompt, effective treatment and long-term disease control. Patients with moderate to severe disease often require systemic treatment with effective & new modalities such as biological-Infliximab. Review will highlight fundamental aspects of infliximab and its use in Psoriasis as well as provide specific comments regarding this monoclonal antibody and its position in of psoriasis in the future treatment.
DOI: http://dx.doi.org/10.3126/jcmsn.v7i1.5977
JCMSN 2011; 7(1): 69-72
Downloads
Downloads
Published
How to Cite
Issue
Section
License
This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.